论文部分内容阅读
目的探讨子宫内膜样腺癌多种多药耐药有关蛋白的表达与性激素水平之间的关系,为帮助解决子宫内膜样腺癌化疗的耐药性,更好地指导临床用药提供实际意义的依据。方法采用单克隆抗体免疫组化SP法,分别测定52例子宫内膜样腺癌组织中及20例正常妇女的增生期子宫内膜组织中GST-π、ToPo-Ⅱ的阳性表达;应用电化学发光免疫测定法检测研究组与对照组的性激素水平。通过统计学分析了解GST-π、ToPo-Ⅱ与性激素水平之间的关系。结果子宫内膜样腺癌GST-π、ToPo-Ⅱ的阳性表达率明显高于正常增生期内膜组织。子宫内膜样腺癌患者血清FSH、LH水平明显高于对照组(P<0.01～0.05),E_2水平明显高于对照组(P<0.01)。E_2血清水平明显影响GST-π、ToPo-Ⅱ的阳性表达率(P<0.01)。结论FSH、LH、E_2水平影响了子宫内膜样腺癌的发生;E_2的血清水平明显的影响了GST-π、ToPo-Ⅱ的阳性表达,提示E_2对子宫内膜样腺癌的化疗可通过影响耐药GST-π、ToPo-Ⅱ的表达发挥着一定的作用。
Objective To investigate the relationship between the expression of multiple multidrug resistance-related proteins and sex hormones in endometrioid adenocarcinoma and to provide practical guidance to help resolve the drug resistance of endometrioid adenocarcinoma chemotherapy and to better guide the clinical use of drugs The basis. Methods Immunohistochemical SP method was used to detect the expression of GST-π and ToPo-Ⅱ in proliferative endometrium from 52 cases of endometrioid adenocarcinoma and 20 cases of normal women. The level of sex hormone in study group and control group was detected by luminescence immunoassay. Through statistical analysis to understand GST-π, ToPo-Ⅱ and sex hormone levels. Results The positive expression rate of ToPo-Ⅱ in GST-π and endometrioid adenocarcinoma was significantly higher than that in normal proliferative endometrium. Serum levels of FSH and LH in patients with endometrioid adenocarcinoma were significantly higher than those in the control group (P <0.01 ~ 0.05), and E2 levels were significantly higher in the patients with endometrioid adenocarcinoma than those in the control group (P <0.01). Serum E_2 level significantly affected the positive rate of GST-π and ToPo-Ⅱ (P <0.01). Conclusions The levels of FSH, LH and E_2 affect the occurrence of endometrial adenocarcinoma. The serum level of E_2 obviously affects the expression of GST-π and ToPo-Ⅱ, which suggests that the chemotherapeutic effect of E_2 on endometrial adenocarcinoma Affect the resistance of GST-π, ToPo-Ⅱ expression plays a role.